Everything you care about in one place

Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.

Get Feeder

fiercepharma.com

FiercePharma

Get the latest updates from FiercePharma directly as they happen.

Follow now 403 followers

Latest posts

Last updated about 6 hours ago

With Austedo at helm, Teva's impressive innovative drug sales signal company's successful metamorphosis

about 6 hours ago

While Teva Pharmaceutical’s multiyear growth streak under CEO Richard Francis showed signs...

AstraZeneca CEO's conservative MFN model excludes reference markets from forecast

about 6 hours ago

As AstraZeneca braces for the impact of the U.S. “most favored nation”...

AbbVie outlines Skyrizi defense against new J&J plaque psoriasis rival Icotyde

about 6 hours ago

Immunology med Skyrizi charted sales growth of 30.9% over 2026's first quarter...

Regeneron's quarterly sales of Eylea drop below $1B for the first time in 8 years

about 9 hours ago

As regulatory delays continue to plague Regeneron's Eylea franchise, quarterly sales for...

New GSK CEO’s first quarter boosted by Shingrix surge as Exdensur stumbles in switch trial

about 11 hours ago

In GSK’s first quarter with Luke Miels as CEO, the company’s flagship...

Pfizer looks to jump start Elrexfio with topline win in second-line myeloma

about 11 hours ago

With a new positive trial readout, the company is aiming to reach...

AstraZeneca restarts $300M investment in UK, but Merck not budging

about 11 hours ago

AstraZeneca has announced it will resume a $300 million investment program in...

Chiesi lays out $1.9B to bolster rare disease offerings with KalVista buyout

about 11 hours ago

As Ekterly nears the one-year anniversary of its approval, Chiesi Group is...

Novartis CEO calls for 'complete rethink' of Europe's drug pricing policies

1 day ago

Novartis CEO Vas Narasimhan says that Europe needs a “complete rethink” on...

Pfizer’s victory in delaying Vyndamax generics is mixed bag for BridgeBio: analysts

1 day ago

Pfizer now anticipates its Vyndamax sales to remain “relatively stable” from 2028...

FDA flags concerns for AstraZeneca's camizestrant, Truqap ahead of advisory committee meeting

1 day ago

The FDA has released briefing documents detailing its concerns for AstraZeneca’s cancer...

FDA turns up heat on Amgen, proposing to rescind approval of Tavneos

1 day ago

The FDA has told Amgen that it is proposing to withdraw the...